Answers are grounded in this paper and cite their sources.
We report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. Antitumor activity was documented. (Funded by Bluebird Bio and Celgene; CRB-401 ClinicalTrials.gov number, NCT02658929.).
No takes yet. Share an insight, caveat, or question.
Raje et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: